

## Lupus: Lupkynis

### Member Information

1. Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Trillium ID #: \_\_\_\_\_ 4. Date of Birth: \_\_\_\_\_ 5. Gender: \_\_\_\_\_

### Prescriber Information

1. Prescriber Name: \_\_\_\_\_ 2. NPI #: \_\_\_\_\_  
3. Requestor Name (Nurse/Office Staff): \_\_\_\_\_  
4. Mailing Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
5. Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_ Fax #: \_\_\_\_\_

### Drug Information

1. Drug Name: \_\_\_\_\_ 2. Strength: \_\_\_\_\_ 3. Quantity Per 30 Days: \_\_\_\_\_  
4. Length of Therapy (in Days): ☐ up to 30 Days ☐ 60 Days ☐ 90 Days ☐ 120 Days ☐ 180 Days ☐ 365 Days

### Clinical Information

#### Initial authorization (answer questions 1-12)

1. Does the member have a diagnosis of active systemic lupus nephritis? ☐ Yes ☐ No
2. Does the member have International Society of Nephrology/Renal Pathology Society (ISN/RPS) biopsy-proven active Class III or IV Lupus Nephritis alone or in combination with Class V Lupus Nephritis? ☐ Yes ☐ No
3. What is the member's urine protein to creatinine (UPCR) ratio? \_\_\_\_\_
4. Is the member age 18 or older? ☐ Yes ☐ No
5. Does the member have hypersensitivity to any component of the medication? ☐ Yes ☐ No
6. Is the medication being administered with strong CYP3A4 inhibitors? (ex. Ketoconazole, itraconazole, clarithromycin) ☐ Yes ☐ No
7. Does the member have severe hepatic impairment? ☐ Yes ☐ No
8. Is the member concomitantly receiving background immunosuppressive therapy? (with the exception of cyclophosphamide) ☐ Yes ☐ No
9. Please list the member's baseline blood pressure \_\_\_\_\_
10. Please list the member's baseline glomerular filtration rate (eGFR) \_\_\_\_\_
11. Will renal function (eGFR) be assessed at regular intervals? ☐ Yes ☐ No
12. Is the medication being prescribed by or in consultation with a rheumatologist? ☐ Yes ☐ No

#### For re-authorization (answer questions 13-15)

13. Does the member continue to meet above criteria? (questions 1-12) ☐ Yes ☐ No
14. Does the member show disease improvement and/or stabilization or improvement in the slope of decline?  
☐ Yes ☐ No
15. Has the member experienced any treatment-restricting adverse effects? (ex. hypertension, neurotoxicities, hyperkalemia) ☐ Yes ☐ No

**\*\*Please attach current progress notes documenting disease status and clinical response to the medicine. \*\***

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_

**(Prescriber Signature Mandatory)**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.